Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

TSIMBERIDOU, APOSTOLIA MARIA

One or more keywords matched the following items that are connected to TSIMBERIDOU, APOSTOLIA MARIA

Item Type	Name
Concept	Vascular Endothelial Growth Factor A
Concept	Receptors, Vascular Endothelial Growth Factor
Academic Article	Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Academic Article	Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Academic Article	Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Academic Article	Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Academic Article	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Academic Article	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
Academic Article	Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Academic Article	Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
Academic Article	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Academic Article	Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer.
Academic Article	Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
Academic Article	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Academic Article	TP53 alterations correlate with response to VEGF/VEGFR inhibitors
Academic Article	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
Academic Article	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Academic Article	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
Academic Article	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
Academic Article	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors.
Academic Article	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Academic Article	First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Search Criteria

Vascular Endothelial Growth Factor A